Why Is Sportradar Stock Going Up?
Sportradar (NASDAQ:SRAD) should be on your radar for a stock…
Buy
52
PBYI Quote, Financials, Valuation and Earnings
Last price:
$3.52
Seasonality move
:
-5.1%
Day range:
$3.36 - $3.53
52-week range:
$2.23 - $6.06
Dividend yield:
0%
P/E ratio:
5.75x
P/S ratio:
0.74x
P/B ratio:
1.89x
Volume:
569.5K
Avg. volume:
445.2K
1-year change:
-34.39%
Market cap:
$174.1M
Revenue:
$230.5M
EPS (TTM):
$0.61
Analysts' Opinion
-
Consensus RatingPuma Biotechnology has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.33, Puma Biotechnology has an estimated upside of 23.46% from its current price of $3.51.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $3.51.
Fair Value
-
According to the consensus of 1 analyst, Puma Biotechnology has 23.46% upside to fair value with a price target of $4.33 per share.
PBYI vs. S&P 500
-
Over the past 5 trading days, Puma Biotechnology has overperformed the S&P 500 by 5.19% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Puma Biotechnology does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Puma Biotechnology revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Puma Biotechnology reported revenues of $59.1M.
Earnings Growth
-
Puma Biotechnology has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Puma Biotechnology reported earnings per share of $0.39.
Enterprise value:
140.2M
EV / Invested capital:
0.88x
Price / LTM sales:
0.74x
EV / EBIT:
3.84x
EV / Revenue:
0.61x
PEG ratio (5yr expected):
0.16x
EV / Free cash flow:
3.61x
Price / Operating cash flow:
4.40x
Enterprise value / EBITDA:
2.92x
Gross Profit (TTM):
$166.1M
Return On Assets:
13.97%
Net Income Margin (TTM):
13.14%
Return On Equity:
47.89%
Return On Invested Capital:
20.19%
Operating Margin:
22.62%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $228M | $235.6M | $230.5M | $72.2M | $59.1M | |
| Gross Profit | $172.9M | $173M | $166.1M | $47.9M | $45.2M | |
| Operating Income | $30.7M | $33.3M | $31M | $14.8M | $13.4M | |
| EBITDA | $21.9M | $47.5M | $48.1M | $19M | $17.7M | |
| Diluted EPS | -- | $0.45 | $0.61 | $0.25 | $0.39 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $146.1M | $140M | $134.3M | $156.2M | $147.7M | |
| Total Assets | $244.2M | $226.6M | $222.1M | $230.5M | $213.3M | |
| Current Liabilities | $114.3M | $109.6M | $77.5M | $99.4M | $96.1M | |
| Total Liabilities | $250.2M | $229M | $200.5M | $177.1M | $121.2M | |
| Total Equity | -$6M | -$2.4M | $21.6M | $53.4M | $92.1M | |
| Total Debt | $98.3M | $97.1M | $98.3M | $99.7M | $67M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$15.8M | $27M | $38.9M | $10.5M | $15.6M | |
| Cash From Investing | $7.1M | -$19.1M | -$20.4M | -$8.2M | -$2.3M | |
| Cash From Financing | $12.2M | -- | -$33.8M | -- | -$11.3M | |
| Free Cash Flow | -$15.8M | $14.4M | $38.9M | $10.4M | $15.6M | |
PBYI
Sector
Market Cap
$174.1M
$39.2M
Price % of 52-Week High
57.97%
45.93%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
-34.39%
-38.63%
Beta (5-Year)
1.334
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$3.39
200-day SMA
Buy
Level
$3.05
Bollinger Bands (100)
Buy
Level
2.8 - 3.3
Chaikin Money Flow
Sell
Level
-36.2M
20-day SMA
Buy
Level
$3.30
Relative Strength Index (RSI14)
Buy
Level
59.53
ADX Line
Buy
Level
24.62
Williams %R
Neutral
Level
-39.3443
50-day SMA
Buy
Level
$3.13
MACD (12, 26)
Buy
Level
0.11
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Sell
Level
-25.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.9519)
Buy
CA Score
(Annual)
Level (-0.1046)
Buy
Beneish M-Score
(Annual)
Level (-2.9052)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.3985)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Stock Forecast FAQ
In the current month, PBYI has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The PBYI average analyst price target in the past 3 months is $4.33.
-
Where Will Puma Biotechnology Stock Be In 1 Year?
According to analysts, the consensus estimate is that Puma Biotechnology share price will rise to $4.33 per share over the next 12 months.
-
What Do Analysts Say About Puma Biotechnology?
Analysts are divided on their view about Puma Biotechnology share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Puma Biotechnology is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Puma Biotechnology's Price Target?
The price target for Puma Biotechnology over the next 1-year time period is forecast to be $4.33 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is PBYI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Puma Biotechnology is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of PBYI?
You can purchase shares of Puma Biotechnology via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Puma Biotechnology shares.
-
What Is The Puma Biotechnology Share Price Today?
Puma Biotechnology was last trading at $3.52 per share. This represents the most recent stock quote for Puma Biotechnology. Yesterday, Puma Biotechnology closed at $3.51 per share.
-
How To Buy Puma Biotechnology Stock Online?
In order to purchase Puma Biotechnology stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Roblox Stock a Buy, Sell or Hold?
Gaming company Roblox (NYSE:RBLX) operates a massive platform that allows…
Is Shopify a Millionaire Maker?
Shopify (NYSE:SHOP) is an eCommerce platform, business services provider and…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 22
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Sell
36
VMI alert for Mar 22
Valmont Industries [VMI] is down 12.54% over the past day.
Buy
61
ALNY alert for Mar 22
Alnylam Pharmaceuticals [ALNY] is up 11.7% over the past day.
